1. Introduction {#sec1-marinedrugs-15-00244}
===============

Research conducted over the past several decades in marine microorganisms has clearly indicated that the ocean is a great resource of microorganisms for producing structurally diverse and biologically active secondary metabolites due to their unique environment \[[@B1-marinedrugs-15-00244]\]. Among all known microbes, the filamentous bacteria in the order Actinomycetales are considered as the most prolific source for producing secondary metabolites \[[@B2-marinedrugs-15-00244],[@B3-marinedrugs-15-00244],[@B4-marinedrugs-15-00244]\], consisting of unusual polyketides, nonribosomal peptides, terpenoids, alkaloids, lipids and others. For instance, marinomycins A--D were isolated from a marine sediment culture of *Marinispora* sp. CNQ-140 showing significant antibacterial activities against drug-resistant pathogens, and selective cancer cell cytotoxicities against six melanoma cell lines \[[@B5-marinedrugs-15-00244]\]. Lajollamycins, a family of nitro group-bearing spiro-β-lactone-γ-lactams were produced by a marine-derived *Streptomyces* sp. \[[@B6-marinedrugs-15-00244]\]. Salinosporamide, a potent proteasome inhibitor with an unusal β-lactone moiety isolated from a marine *Salinospora tropica* has been entered human clinical trial for the treatment of multiple myeloma \[[@B7-marinedrugs-15-00244]\]. In our search for new bioactive compounds from marine microorganisms, we isolated actinomycete strains from a marine sediment sample in the Coast of Hainan Island of China. During the screening, we found one of the isolated strains, NA02069, was designated as *Streptomyces chartreusis* based on its 16s rDNA sequence. *S. chartreusis* has been previously reported to produce chartreusin, chrymutasins, and calcimycin \[[@B8-marinedrugs-15-00244],[@B9-marinedrugs-15-00244]\], all of which belong to the family of polyketides. In order to enrich the diversity of the compounds from this strain, we became interested in *S. chartreusis* NA02069 to find whether different compounds can be produced. In this study, we report the isolation and structure elucidation of two new (**1**) and (**2**) and a known (**3**) alkaloid compounds ([Figure 1](#marinedrugs-15-00244-f001){ref-type="fig"}). Compounds **1** and **2** were evaluated for their antimicrobial and acetylcholinesterase inhibitory activities.

2. Results {#sec2-marinedrugs-15-00244}
==========

2.1. Taxonomy and Phylogenetic Analysis of the Strain NA02069 {#sec2dot1-marinedrugs-15-00244}
-------------------------------------------------------------

The 16s rDNA sequence of strain NA02069 was amplified by polymerase chain reaction (PCR) and sequenced. After alignment analysis using Basic Logic Alignment Search Tool (BLAST), strain NA02069 showed 100% identities (1352 bp) to a subclade, which also included the type strains of *Streptomyces chartreusis* ISP 5085, *S. chartreusis* DA10203, and *S. chartreusis* NBRC 12753 ([Figure 2](#marinedrugs-15-00244-f002){ref-type="fig"}). Thus, the strain was assgined as *Streptomyces chartreusis* NA02069 \[[@B10-marinedrugs-15-00244]\].

2.2. Isolation and Structure Elucidation {#sec2dot2-marinedrugs-15-00244}
----------------------------------------

The actinomycete strain was cultured at 28 °C with 130 rpm agitation in YEME medium (20 L) medium. After 10 days, the filtrate of the fermented culture broth was extracted repeatedly with ethyl acetate three times to afford a brown crude extract, which was subjected to repeated column chromatography (CC) over silica-gel, Sephadex LH-20, octadecylsilane (ODS) and high performance liquid chromatography (HPLC) to yield two new alkaloids, strepchazolins A (**1**), B (**2**), and a known Compound (**3**). The known compound was identified as streptazolin by comparison of their spectroscopic data with those in the literature \[[@B11-marinedrugs-15-00244]\].

Strepchazolin A (**1**) was obtained as a pale yellow crystal. Its molecular formula was determined as C~12~H~17~NO~3~ on the basis of the sodium-adduct high-resolution ESIMS ion at *m/z* 246.1116 \[M + Na\]^+^, (calcd for C~12~H~17~NO~3~Na, 246.1101) along with the ^13^C NMR data ([Table 1](#marinedrugs-15-00244-t001){ref-type="table"}). The ^1^H NMR spectrum of **1** in methanol-*d*~4~ displayed two double-bond protons (*δ*~H~ 5.85 and 6.05), three oxygen/nitrogen substituted methine protons (*δ*~H~ 4.51, 4.56, and 4.31), four methylene protons (*δ*~H~ 3.16, 3.83, 2.30 and 2.30), and six methyl protons in two methyl groups (*δ*~H~ 1.38 and 2.19). The ^13^C NMR spectrum showed one carbonyl carbon (*δ*~C~ 175.4), four resonances in the double bond region (*δ*~C~ 148.5, 140.7, 130.3, and 117.8), three oxygen/nitrogen substituted carbons (*δ*~C~ 81.0, 68.4, and 64.7), and four sp^3^-hybrized quaternary carbons (*δ*~C~ 46.2, 25.8, 22.8, and 22.6). Further analysis of its HSQC spectrum assigned all signals for ^1^H-^13^C one bond correlations. The ^1^H-^1^H COSY spectrum of H-1 (*δ*~H~ 1.38)/H-2 (*δ*~H~ 4.51); H-4 (*δ*~H~ 5.85)/H-5 (*δ*~H~ 4.56)/H-6 (*δ*~H~ 4.31); and H-8 (*δ*~H~ 6.05)/H-9 (*δ*~H~ 2.30)/H-10 (*δ*~H~ 3.16 and 3.83) revealed three spin systems are present in **1** ([Figure 3](#marinedrugs-15-00244-f003){ref-type="fig"}). The HMBC correlations of H-1/C-3, H-2/C-4, H-6/C-8, H-9/C-7 suggested the above three spin systems were connected through C-2-C-3-C-4, and C-6-C-7-C-8, respectively. Moreover, the HMBC correlations of H-2/C-7, H-4/C-7, as well as H-8/C-3 revealed the connectivity between C-3-C-7, revealing the presence of a cyclopentene moiety. The HMBC correlations of H-6/C-8 and H-10/C-8 together with their typical nitrogen substituted chemical shifts for *δ*~C-6~ 68.4/*δ*~H-6~ 4.31 and *δ*~C-10~ 46.2/*δ*~H-10a~ 3.83 and *δ*~H-10b~ 3.16 indicated the presence of a tetrahydropyridine moiety. Finally, the HMBC correlation of H-10 and H-12 with carbonyl carbon C-11 revealing that an acetyl group was anchored at the N-atom. The remaining two hydroxyl groups were connected at C-2 (*δ*~C~ 64.7) and C-5 (*δ*~C~ 81.0) on the basis of their chemical shifts. Thus, the planar structure of **1** was established.

The full structure and absolute configurations at all chiral centers of **1** were assigned based on the X-ray crystallographic analysis. A high-quality single crystal was obtained from slow evaporation of compound **1** in acetone/MeOH solutions at low temperature. The X-ray crystallography data measured in a Cu Kα radiation in low temperature fully confirmed the proposed structure and determined the absolute configuration of **1** as 2*R*, 5*S*, and 6*S* ([Figure 4](#marinedrugs-15-00244-f004){ref-type="fig"}).

Strepchazolin B (**2**) was obtained as a pale yellow oil, which analyzed for the same molecular formula, C~12~H~17~NO~3~, as **1** by HRESIMS (obsd \[M + Na\]^+^ at *m/z* 246.1103, calcd for C~12~H~17~NO~3~Na 246.1101) in combination with interpretation of ^1^H and ^13^C NMR data ([Table 1](#marinedrugs-15-00244-t001){ref-type="table"}). The ^13^C NMR data of **2** were almost identical to those of **1**, however the ^1^H NMR spectra between **1** and **2** were slightly different ([Figure S17](#app1-marinedrugs-15-00244){ref-type="app"}). Further interpretation of HSQC, HMBC and ^1^H-^1^H COSY spectral data ([Figure 5](#marinedrugs-15-00244-f005){ref-type="fig"}) of **2** established that the planar structure of compound **2** is identical to that of **1**.

In the NOESY spectrum of **2** ([Figure 5](#marinedrugs-15-00244-f005){ref-type="fig"}), the NOE correlation between H-5 and H-12 demonstrated that H-5 and H-6 possessed β and α-orientations, respectively, consistent with those observed in **1**. The chemical shifts for H-5/C-5 and H-6/C-6 in **2** are the same with those in **1**, which suggest configurations of C-5 and C-6 in **2** are the same to **1**. The absolute configuration of C-2 in compound **2** was determined by a modified Mosher's method \[[@B12-marinedrugs-15-00244],[@B13-marinedrugs-15-00244]\]. Using low temperature control of the esterify reaction (MTPA-Cl/pyridine), we were able to regioselectively esterified the C-2 hydroxyl group in **2**. The ^1^H chemical shifts of **2a** and **2b** were assigned by analyzing their HSQC and ^1^H-^1^H COSY NMR spectra. The Δ*δ* values between (*S*) and (*R*)-MTPA esters demonstrated that C-2 possessed an *S*-configuration ([Figure 6](#marinedrugs-15-00244-f006){ref-type="fig"}), which is opposite to that in compound **1** as expected.

2.3. Bioactivities of Strepchazolins {#sec2dot3-marinedrugs-15-00244}
------------------------------------

As a primary screen for antibacterial and acetylcholinesterase inhibitory activities, the results were shown in [Table 2](#marinedrugs-15-00244-t002){ref-type="table"} and [Table 3](#marinedrugs-15-00244-t003){ref-type="table"}. Compound **1** exhibited weak antibacterial activity against *Bacillus subtilis* with its MIC value of 64.0 μM, and weak acetylcholinesterase inhibitory activity with IC~50~ value of 50.6 μM. However, compound **2**, the diastereoisomer of **1**, is almost inactive ([Table 2](#marinedrugs-15-00244-t002){ref-type="table"} and [Table 3](#marinedrugs-15-00244-t003){ref-type="table"}).

3. Experimental Section {#sec3-marinedrugs-15-00244}
=======================

3.1. General Methods {#sec3dot1-marinedrugs-15-00244}
--------------------

Optical rotation was measured in MeOH on a Rudolph Research Analytical Autopol IV automatic polarimeter. Mass spectra were acquired on an Agilent 6250 TOF LC-MS instrument equipped with an electrospray ionization (ESI) probe operating in positive-ion mode with direct infusion. NMR experiments were accomplished in Methanol-*d*~4~ on a Bruker DRX-600 spectrometer with ^1^H and ^13^C nuclei observed at 600 and 150 MHz, respectively, with TMS or solvent signal adopted as internal standards. Silica gel (200--300 mesh) for CC (column chromatography) and GF254 (10--20 µm) for TLC (thin layer chromatography) were purchased from Qingdao Marine Chemical Company, China. Sephadex LH-20 were purchased from GE Biotech, USA. Semi-preparative reverse phase-high performance liquid chromatography (RP-HPLCs) were accomplished on an Eclipse XDB-C18 column (5 μM, 250 × 9.4 mm) from Agilent Technologies Inc. USA (Santa Clara, CA, USA). All chemicals used in the study were of analytical grade and HPLC grade.

3.2. Strain Isolation and Cultivation {#sec3dot2-marinedrugs-15-00244}
-------------------------------------

*S. chartreusis* NA02069 was isolated from a sediment from the coast of Hainan Island, China. The purified strain was cultured in modified 38^\#^ medium plate (consisting 4 g yeast extract, 4 g glucose, 5 g malt extract, 1 mL multi-vitamins, 20 g agar, 27 g sea salt in 1 L water) at 28 °C for 4 days. After 2 days of incubation in 10 flasks each containing 100 mL Tryptone Soya Broth medium (Weigh 30 g to 1 L of water) at 28 °C with 130 rpm agitation, the seed cultures were used to inoculate 100 flasks each containing 200 mL YEME medium (consisting 4 g yeast extract, 4 g glucose, 10 g malt extract, 27 g sea salt in 1 L water).

3.3. Isolation of Compounds ***1***, ***2*** and ***3*** {#sec3dot3-marinedrugs-15-00244}
--------------------------------------------------------

After 10 days cultivation, the filtrate (20 L) of the fermented culture broth was extracted three times using ethyl acetate. The organic extract was enriched in vacuo to yield 3.2 g of a brown thick oil material. The extract was subjected to column chromatography (CC) over silica gel fractionated with 500 mL mixtures of petroleum ether-ethyl acetate (*v/v*, 100:0, 100:2, 100:4, 100:10, 100:50, 0:100), CH~2~Cl~2~-MeOH (*v/v*, 100:0, 100:2, 100:4, 100:10, 100:50, 0:100) to afford 17 fractions (04-1→04-17 collected according to TLC monitoring). 04-5 (0.5 g) was subsequently separated by ODS chromatography with H~2~O-MeOH (*v/v*, 70:30, 60:40, 50:50, 40:60, 30:70, 0:100) to afford 8 fractions (04-5-1→04-5-8 collected according to TLC monitorings). Finally, compounds **1** (11.2 mg), **2** (9.4 mg), **3** (6.7 mg) were eluted as pure compounds using semi-preparative reverse-phase HPLC (2 mL/min, detector UV λ~max~ 254 nm, MeOH/H~2~O 38:62).

Compound **1**: Pale yellow crystal; \[α\]${}_{D}^{25}$ −68° (*c* 0.10, MeOH); m.p.: 125--126 °C; UV (MeOH) λ~max~ (log *ε*): 217 (0.791), 281 (0.391) nm. HR-ESI-MS (*m*/*z*): 246.1116 \[M + Na\]^+^ (calcd. for C~12~H~17~NO~3~Na, 246.1101); ^1^H and ^13^C NMR data are listed in [Table 1](#marinedrugs-15-00244-t001){ref-type="table"}.

Compound **2**: pale yellow oil; \[α\]${}_{D}^{25}$ −26° (*c* 0.1, MeOH); UV (MeOH) λ~max~ (log ε): 217 (0.714), 281 (0.224) nm. HR-ESI-MS (*m*/*z*): 246.1103 \[M + Na\]^+^ (calcd. for C~12~H~17~NO~3~Na, 246.1101); ^1^H and ^13^C NMR data are listed in [Table 1](#marinedrugs-15-00244-t001){ref-type="table"}.

3.4. Crystal Data of ***1*** {#sec3dot4-marinedrugs-15-00244}
----------------------------

Crystal data of compound **1** was collected on an Agilent Xcalibur Nova single-crystal diffractometer using Cu Kα radiation in low temperature. The structures were solved by direct methods using SHELXS-97 and refined by means of full-matrix least squares. Crystal data of compound **1** have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication CCDC 1557150.

Crystal data for **1**: molecular formula C~12~H~17~NO~3~, *M*~r~ = 223.26, monoclinic crystals, *a* = 4.37020 (10) Å, *b* = 14.0896 (4) Å, *c* = 9.1364 (2) Å, *Z* = 2, *μ* = 0.779 mm^−1^ and *F* (000) = 240; Crystal dimensions: 0.180 × 0.150 × 0.100 mm^3^, Volume = 558.42 (2) Å^3^, *R* (reflections) = 0.0185 (1573), *R* indices \[I \> 2 sigma(I)\] *R*~1~ = 0.0278, *wR*~2~ = 0.0739.

3.5. Formation of the (S)- and (R)-MTPA Esters of ***2*** {#sec3dot5-marinedrugs-15-00244}
---------------------------------------------------------

To a solution of **2** (0.3 mg, 1.3 μmol) in anhydrous pyridine (0.15 mL), (*R*)-(−)-MTPA chloride (1.6 mg, 6.5 μmol) was added, and the reaction mixture was stirred at 0 °C for 1 h. Methanol (0.3 mL) was added to the reaction mixture to terminate the reaction. The solvent was evaporated under reduced pressure, and the residue was purified by HPLC using Acetonitrile-H~2~O (65:35→90:10) as the eluent to afford (*S*)-MTPA ester **2a** (0.1 mg) as a colorless oil. **2** (0.3 mg, 1.3 μmol) and (*S*)-(+)-MTPA chloride (1.6 mg, 6.5 μmol) were treated with the same procedure to afford (*R*)-MTPA ester **2b** (0.1 mg) as a colorless oil.

*S-*MTPA ester (**2a**): colorless oil; HR-ESI-MS (*m*/*z*): 462.1486 \[M + Na\]^+^ (calcd. for C~22~H~24~F~3~NO~5~Na, 462.1499); ^1^H NMR data are listed in [Table S1 of Supplementary Materials](#app1-marinedrugs-15-00244){ref-type="app"}.

*R-*MTPA ester (**2b**): colorless oil; HR-ESI-MS (*m*/*z*): 462.1500 \[M + Na\]^+^ (calcd. for C~22~H~24~F~3~NO~5~Na, 462.1499); ^1^H NMR data are listed in [Table S1 of Supplementary Materials](#app1-marinedrugs-15-00244){ref-type="app"}.

3.6. Antibacterial Assay {#sec3dot6-marinedrugs-15-00244}
------------------------

Following the described procedure \[[@B14-marinedrugs-15-00244]\], the antibacterial activities of compounds **1** and **2** were tested in 96-well microplates. The tested bacterial strain, Bacillus subtilis, was preserved in State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China. The strain was grow on a MHB solid medium and then cultured 24 h in liquid medium. The testing system consists of 50 μL diluted bacterial solution (\~105 CFU/mL), 49 μL fresh medium and 1 μL tested compound. The microplate was vibrated for homogenizing the mixture and then incubated at 37 °C for 24 h. MIC (Minimal Inhibitory Concentration) accounts for the magnitude of the antibacterial activity.

3.7. Bioactivity Assay {#sec3dot7-marinedrugs-15-00244}
----------------------

The acetylcholinesterase inhibitory activities were assayed according to a method reported in the literature \[[@B15-marinedrugs-15-00244]\]. Briefly, compounds **1** and **2** were dissolved in DMSO and diluted to different concentrations using 0.1 M phosphate buffer (pH 8.0). The enzymatic reaction was triggered by adding 20 μL of 3.33 mM 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB, Sigma-Aldrich, St. Louis, MO, USA) to the reaction system (consisting of 2 μL of the tested sample solution, 20 μL of 0.35 U/mL AChE solution and 20 μL of 3.33 mM 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB) and 138 μL of phosphate buffer). Reaction substances were detected through Microplate Reader by measuring the absorbance at 410 nm. Meanwhile, Huperzine A and DMSO were used as positive and negative controls, respectively. Each test was performed in triplicate. Then IC~50~ of each compound was calculated by SPSS 16.0 \[[@B16-marinedrugs-15-00244]\].

4. Conclusions {#sec4-marinedrugs-15-00244}
==============

In summary, two new alkaloids, strepchazolins A (**1**) and B (**2**), as well as a known compound streptazolin (**3**) were isolated from a marine actinomycete *S. chartreusis* NA02069. Their structures were determined using a combination of HRESIMS and NMR spectroscopic and X-ray crystallographic data together with modified Mosher's method. Compounds **1** showed weak anti-*Bacillus subtilis* activity and weak inhibitory activity against acetylcholinesterase, while its diastereoisomer, compound **2**, is almost inactive. The research described here further indicates that marine actinomycetes are a rich source for new bioactive natural products that could lead to the discovery of new drugs or drug leads.
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marinedrugs-15-00244-t001_Table 1

###### 

^1^H and ^13^C NMR (600 and 150 MHz in methanol-*d*~4~) data for compounds **1** and **2**.

  No.   1             2                                   
  ----- ------------- --------------------- ------------- ---------------------
  1     22.6, CH~3~   1.38, d (6.5)         22.7, CH~3~   1.36, d (6.5)
  2     64.7, CH      4.51, q (6.5)         64.8, CH      4.55, q (6.5)
  3     148.5, C                            149.2, C      
  4     130.3, CH     5.85, brs             129.0, CH     5.86, brs
  5     81.0, CH      4.56, m               81.0, CH      4.56, m
  6     68.4, CH      4.31, brs             68.4, CH      4.30, brs
  7     140.7, C                            140.9, C      
  8     117.8, CH     6.05, m               117.2, CH     5.96, m
  9     25.8, CH~2~   2.30, m               25.8, CH~2~   2.30, m
  10    46.2, CH~2~   3.16, td (12.2,2.9)   46.2, CH~2~   3.16, td (12.2,2.9)
                      3.83, dt (12.2,2.9)                 3.83, dt (12.2,2.9)
  11    175.4, C                            175.4, C      
  12    22.8, CH~3~   2.19, s               22.8, CH~3~   2.20, s

marinedrugs-15-00244-t002_Table 2

###### 

The antimicrobial MIC (μM) of compounds **1** and **2**.

                        1      2         Rifampicin
  --------------------- ------ --------- ------------
  *Bacillus subtilis*   64.0   \>128.0   1.0

marinedrugs-15-00244-t003_Table 3

###### 

In vitro acetylcholinesterase (AChE) inhibitory activity of compounds **1** and **2**.

  Compound      1      2         Huperzine A
  ------------- ------ --------- -------------
  IC~50~ (μM)   50.6   \>100.0   4.3
